-
Je něco špatně v tomto záznamu ?
Role of clinicopathological variables in predicting recurrence and survival outcomes after surgery for non-metastatic renal cell carcinoma: Systematic review and meta-analysis
M. Majdoub, T. Yanagisawa, F. Quhal, E. Laukhtina, M. von Deimling, T. Kawada, P. Rajwa, A. Bianchi, M. Pallauf, H. Mostafaei, M. Chlosta, B. Pradere, PI. Karakiewicz, M. Schmidinger, R. Rub, SF. Shariat
Jazyk angličtina Země Spojené státy americké
Typ dokumentu metaanalýza, systematický přehled, časopisecké články
PubMed
38009868
DOI
10.1002/ijc.34793
Knihovny.cz E-zdroje
- MeSH
- karcinom z renálních buněk * patologie MeSH
- ledviny patologie MeSH
- lidé MeSH
- nádory ledvin * patologie MeSH
- nefrektomie MeSH
- prognóza MeSH
- retrospektivní studie MeSH
- staging nádorů MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- metaanalýza MeSH
- systematický přehled MeSH
Renal cell carcinoma (RCC) represents 2% of all diagnosed malignancies worldwide, with disease recurrence affecting 20% to 40% of patients. Existing prognostic recurrence models based on clinicopathological features continue to be a subject of controversy. In this meta-analysis, we summarized research findings that explored the correlation between clinicopathological characteristics and post-surgery survival outcomes in non-metastatic RCC patients. Our analysis incorporates 99 publications spanning 140 568 patients. The study's main findings indicate that the following clinicopathological characteristics were associated with unfavorable survival outcomes: T stage, tumor grade, tumor size, lymph node involvement, tumor necrosis, sarcomatoid features, positive surgical margins (PSM), lymphovascular invasion (LVI), early recurrence, constitutional symptoms, poor performance status (PS), low hemoglobin level, high body-mass index (BMI), diabetes mellitus (DM) and hypertension. All of which emerged as predictors for poor recurrence-free survival (RFS) and cancer-specific survival. Clear cell (CC) subtype, urinary collecting system invasion (UCSI), capsular penetration, perinephric fat invasion, renal vein invasion (RVI) and increased C-reactive protein (CRP) were all associated with poor RFS. In contrast, age, sex, tumor laterality, nephrectomy type and approach had no impact on survival outcomes. As part of an additional analysis, we attempted to assess the association between these characteristics and late recurrences (relapses occurring more than 5 years after surgery). Nevertheless, we did not find any prediction capabilities for late disease recurrences among any of the features examined. Our findings highlight the prognostic significance of various clinicopathological characteristics potentially aiding in the identification of high-risk RCC patients and enhancing the development of more precise prediction models.
Department of Urology 2nd Faculty of Medicine Charles University Prague Czech Republic
Department of Urology Comprehensive Cancer Center Medical University of Vienna Vienna Austria
Department of Urology Jagiellonian University hospital Krakow Poland
Department of Urology King Fahad Specialist Hospital Dammam Saudi Arabia
Department of Urology La Croix Du Sud Hospital Quint Fonsegrives France
Department of Urology Medical University of Silesia Zabrze Poland
Department of Urology The Jikei University School of Medicine Tokyo Japan
Department of Urology University Medical Center Hamburg Eppendorf Hamburg Germany
Department of Urology University of Texas Southwestern Medical Center Dallas Texas USA
Department of Urology University of Verona Azienda Ospedaliera Universitaria Integrata Verona Italy
Department of Urology Weill Cornell Medical College New York New York USA
Hourani Center for Applied Scientific Research Al Ahliyya Amman University Amman Jordan
Institute for Urology and Reproductive Health Sechenov University Moscow Russia
Karl Landsteiner Institute of Urology and Andrology Vienna Austria
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24006614
- 003
- CZ-PrNML
- 005
- 20240423155410.0
- 007
- ta
- 008
- 240412s2024 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1002/ijc.34793 $2 doi
- 035 __
- $a (PubMed)38009868
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Majdoub, Muhammad $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u Department of Urology, Hillel Yaffe Medical Center, Affiliated to Technion-Israeli Institute of Technology, Hadera, Israel $1 https://orcid.org/0000000228727047
- 245 10
- $a Role of clinicopathological variables in predicting recurrence and survival outcomes after surgery for non-metastatic renal cell carcinoma: Systematic review and meta-analysis / $c M. Majdoub, T. Yanagisawa, F. Quhal, E. Laukhtina, M. von Deimling, T. Kawada, P. Rajwa, A. Bianchi, M. Pallauf, H. Mostafaei, M. Chlosta, B. Pradere, PI. Karakiewicz, M. Schmidinger, R. Rub, SF. Shariat
- 520 9_
- $a Renal cell carcinoma (RCC) represents 2% of all diagnosed malignancies worldwide, with disease recurrence affecting 20% to 40% of patients. Existing prognostic recurrence models based on clinicopathological features continue to be a subject of controversy. In this meta-analysis, we summarized research findings that explored the correlation between clinicopathological characteristics and post-surgery survival outcomes in non-metastatic RCC patients. Our analysis incorporates 99 publications spanning 140 568 patients. The study's main findings indicate that the following clinicopathological characteristics were associated with unfavorable survival outcomes: T stage, tumor grade, tumor size, lymph node involvement, tumor necrosis, sarcomatoid features, positive surgical margins (PSM), lymphovascular invasion (LVI), early recurrence, constitutional symptoms, poor performance status (PS), low hemoglobin level, high body-mass index (BMI), diabetes mellitus (DM) and hypertension. All of which emerged as predictors for poor recurrence-free survival (RFS) and cancer-specific survival. Clear cell (CC) subtype, urinary collecting system invasion (UCSI), capsular penetration, perinephric fat invasion, renal vein invasion (RVI) and increased C-reactive protein (CRP) were all associated with poor RFS. In contrast, age, sex, tumor laterality, nephrectomy type and approach had no impact on survival outcomes. As part of an additional analysis, we attempted to assess the association between these characteristics and late recurrences (relapses occurring more than 5 years after surgery). Nevertheless, we did not find any prediction capabilities for late disease recurrences among any of the features examined. Our findings highlight the prognostic significance of various clinicopathological characteristics potentially aiding in the identification of high-risk RCC patients and enhancing the development of more precise prediction models.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a karcinom z renálních buněk $x patologie $7 D002292
- 650 12
- $a nádory ledvin $x patologie $7 D007680
- 650 _2
- $a ledviny $x patologie $7 D007668
- 650 _2
- $a prognóza $7 D011379
- 650 _2
- $a nefrektomie $7 D009392
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a staging nádorů $7 D009367
- 655 _2
- $a metaanalýza $7 D017418
- 655 _2
- $a systematický přehled $7 D000078182
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Yanagisawa, Takafumi $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u Department of Urology, The Jikei University School of Medicine, Tokyo, Japan
- 700 1_
- $a Quhal, Fahad $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u Department of Urology, King Fahad Specialist Hospital, Dammam, Saudi Arabia
- 700 1_
- $a Laukhtina, Ekaterina $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia $1 https://orcid.org/0000000289530272
- 700 1_
- $a von Deimling, Markus $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
- 700 1_
- $a Kawada, Tatsushi $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
- 700 1_
- $a Rajwa, Pawel $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u Department of Urology, Medical University of Silesia, Zabrze, Poland
- 700 1_
- $a Bianchi, Alberto $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy
- 700 1_
- $a Pallauf, Maximilian $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u Department of Urology, Paracelsus Medical University Salzburg, University Hospital Salzburg, Salzburg, Austria
- 700 1_
- $a Mostafaei, Hadi $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u Men's Health and Reproductive Health Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
- 700 1_
- $a Chlosta, Marcin $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u Department of Urology, Jagiellonian University hospital, Krakow, Poland
- 700 1_
- $a Pradere, Benjamin $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u Department of Urology, La Croix Du Sud Hospital, Quint Fonsegrives, France
- 700 1_
- $a Karakiewicz, Pierre I $u Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Canada
- 700 1_
- $a Schmidinger, Manuela $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
- 700 1_
- $a Rub, Ronen $u Department of Urology, Hillel Yaffe Medical Center, Affiliated to Technion-Israeli Institute of Technology, Hadera, Israel
- 700 1_
- $a Shariat, Shahrokh F $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia $u Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman, Jordan $u Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas, USA $u Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic $u Department of Urology, Weill Cornell Medical College, New York, New York, USA $u Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria
- 773 0_
- $w MED00002298 $t International journal of cancer $x 1097-0215 $g Roč. 154, č. 7 (2024), s. 1309-1323
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38009868 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240412 $b ABA008
- 991 __
- $a 20240423155407 $b ABA008
- 999 __
- $a ok $b bmc $g 2080927 $s 1216381
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 154 $c 7 $d 1309-1323 $e 20231127 $i 1097-0215 $m International journal of cancer $n Int J Cancer $x MED00002298
- LZP __
- $a Pubmed-20240412
